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Adverse drug reactions (ADRs), defined as all noxious and unin-
tended responses to a medicinal product related to any dose, are 
common affecting 10%-20% of hospitalized patients and up to 25% 
of outpatients.1 As such they are a major burden on healthcare sys-
tems and there is a pressing need to understand both patient and 
drug-related risk factors and mechanisms that contribute to these 
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Abstract
Direct oral anticoagulants (DOACs) have rapidly become the drug class of choice 
for anticoagulation therapy in secondary care. It is known that gastrointestinal hem-
orrhage are potential side effects of the DOAC drug class. In this study we have 
investigated the relevance of molecular structure and on/off-target pharmacology 
as a predictor of adverse drug reactions (ADRs) for the DOAC drug class. Use of 
the Reaxys MedChem module allowed for data mining of all possible reported off-
target effects of the DOAC class members. For the first time, the MHRA Yellow 
card database in combination with prescribing rates in the United Kingdom (data for 
n	=	30	566	936	DOAC	Rx (up to 2017) and ADR data n = 22 275 (up to 2018)) were 
used for our data comparison of DOACs. From the underlying reported data, we 
were able to rank the DOACs in terms of the likely adverse events we would expect 
to observe. We identified potential risks of ADRs based on the DOACs pharmacol-
ogy including the expected GI hemorrhage, but also the unexpected risk of stroke, 
pulmonary embolism and kidney injury. Statistically significant (P < .001) differences 
were found between all DOACs and their total number of ADRs. Although the risks 
are small, strong statistical correlation between observed pharmacology and national 
ADR data is observed in three out of the five areas of concern.
K E Y W O R D S
DOACs, risk factors, selectivity profile, Yellow Card
2 of 10  |     FERRO Et al.
events. Limited access to large and diverse patient populations in 
clinical trials, untested drug co-administrations, and longer term 
treatments often result in post-marketing labeling and occasional 
withdrawals.2 Furthermore, the occurrence of off-target ADRs are 
not predictable based on the drug's specific therapeutic effect.1 
Therefore, postmarketing surveillance (PMR) schemes have been 
introduced in many countries and internationally to improve pa-
tient safety by identifying previously unrecognized ADRs, drug in-
teractions, and patient subgroup vulnerability.3-5 However, these 
schemes are reactive rather than proactive.
Direct oral anticoagulants (DOACs) include the sole direct 
thrombin inhibitor (Dabigatran) and three direct factor Xa inhib-
itors (Rivaroxaban, Apixaban and Edoxaban) were first licensed in 
the United Kingdom in 2008 (Dabigatran), 2012 (Rivaroxaban and 
Apixaban), and 2015 (Edoxaban), respectively. DOACs are currently 
used for the treatment of venous thrombo-embolism (VTE), throm-
boprophylaxis, prevention of stroke, and embolization in nonvalvu-
lar atrial fibrillation (AF) and are rapidly becoming the drug class of 
choice for anticoagulation therapy, superseding warfarin.6,7 DOACs 
are preferred for their ease of use, favorable pharmacokinetics, 
fewer reported drug interactions, and lack of monitoring require-
ments.8 Clinical trials have identified that DOACs have very similar 
efficacy profiles compared to warfarin and are noninferior, resulting 
in lower incidences of some major bleeds. In contrast, DOACs are as-
sociated with higher risks of gastrointestinal hemorrhage (GI) when 
compared to warfarin.9-12 There are concerns regarding other poten-
tially serious ADRs linked with the DOAC drug class and significant 
mortality rates, such as liver impairment and central nervous system 
disorders.7,13-18
Recent studies have revealed that drugs believed to be highly se-
lective frequently address multiple target proteins.19 In this study we 
considered whether the on- and off-target selectivity profiles1,2,20-26 
for a drug class with a novel mechanism of action (DOACs) could 
inform or predict the likelihood of serious adverse events within a 
real-world population. This research aims to identify ADRs of the 
four DOACs currently available in the United Kingdom, and to dis-
cover whether any of these could have potentially been predicted by 
linking back to their molecular properties.
1.1 | Aims and objectives
To predict potential adverse drug reactions based on the identified 
DOAC chemical properties and pharmacology. To identify if the pre-
dicted adverse drug reactions are statistically relevant.
2  | MATERIAL S AND METHODS
2.1 | Chemical properties and pharmacology
Reaxys® Medicinal Chemistry database was used to characterize 
the chemical properties, including metabolism/clearance pathways, 
volume of distribution (Vdss) and plasma protein binding (PPB), and 
selectivity profiles for all four DOACs.27 How drugs are cleared from 
the body can give an indication of areas for ADRs to occur.28 Full re-
sults are included in Table S1. In particular the following parameters 
of interest were extracted:
2.1.1 | Target affinity
To facilitate comparisons of data from different publications, 
Reaxys® medicinal chemistry uses pX values. These are normal-
ized values assigned to the data to enable quantification of the 
substance-target affinity and comparison of disparate informa-
tion. This allowed for a systematic interrogation of the available 
literature, combined with identifying the primary literature source 
to convert the pX value into a relatable pIC50 (Negative log of the 
half maximal inhibitory concentration (IC50 value), when converted 
to molar) value. A threshold of ~10 μmol/L (pX = 5) for at least one 
DOAC was used to exclude biologically insignificant off-target in-
teractions.19 Extracted pX data were compared to the primary lit-
erature using SciFinder, PubMed, Reaxys, EMBASE, and PubChem 
databases.
2.1.2 | Molecular obesity and on-target 
efficiency metrics
Molecular obesity is the term for the anticipated degree of nonspe-
cific interacting lipophilic components of a drug based on the corre-
lation of logP (where P is the partition coefficient = concentration of 
solute in octanol divided by the concentration of solute in water)29,30 
with promiscuity of thousands of pharmaceutical entities. High mo-
lecular weight and logP are correlated to the propensity of a drug 
having more off-target behavior.30,31
The Lipophilic Ligand Efficiency (LLE) index, a measure of how 
efficient a drug binds to its target excluding nonspecific entropic 
factors was calculated using LLE = pIC50	−	log	P.	The	parameter	LLE	
is considered an important parameter to normalize potency relative 
to lipophilicity.32,33 A value of less than five is suggested to be asso-
ciated with an increased risk of toxicity for any given compound.31
2.1.3 | Blood-brain barrier penetration
The risk of neurological ADRs is markedly increased if a drug can 
penetrate the blood brain barrier (BBB). Thresholds for BBB pene-
tration are as follows: molecular weight < 450 Da; <6 hydrogen bond 
donors (HBD); <2 hydrogen bond acceptors (HBA); Neutral or basic 
drug molecule as defined by the pKa (negative base10 logarithm of 
the acid dissociation constant; the lower the pKa value the stronger 
the	 acid);	 topological	 polar	 surface	 area	 (tPSA)	 <90	Å;	 logD7.5 1-3 
(logD is the distribution constant of a drug between the aqueous 
and lipid phases at pH 7.5); and low affinity to efflux P-glycoprotein 
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mechanisms. The more of these properties possessed by a drug the 
greater the likelihood of BBB penetration.34,35
2.2 | Yellow Card Scheme
The Yellow Card Scheme run by the Medicines and Healthcare 
Products Regulatory Agency (MHRA), administers the collection of 
data relating to suspected ADRs in the United Kingdom. It was devised 
to improve patient safety and identification of adverse patient events 
in	1964	in	the	wake	of	the	thalidomide	disaster.5 Adverse patient event 
data were collected from the Yellow Card Scheme Interactive Drug 
Analysis Profiles web portal (https://yello wcard.mhra.gov.uk/iDAP/) 
up to November 2018.36 The spontaneous reporting system had pro-
cessed information from 2008 up to October 2018.
2.3 | Prescribing data
UK prescribing data were collected from Open Prescribing data-
base (https://openp rescr ibing.net/) and provide data on all National 
Health Service (NHS) prescribing in English primary care.37,38
2.4 | Prediction approach used
Meeting the chemical properties (eg, LLE < 5 for general ADR risk) 
and pharmacology definitions (eg, pX > 5 for specific ADR risks) out-
lined above were used as predictors of ADRs. The use of off-target 
inhibition data to predict ADRs was used with the caveat of biologi-
cally relevant levels of inhibition (<10 µmol/L) for the target of inter-
est. If a drug had potent biological inhibition of an off-target protein, 
the protein's biological relevance was investigated via a separate lit-
erature search algorithm. Bringing together these disparate informa-
tion sources generated possible ADR effects.
2.5 | Statistical analysis
Data were tabulated from the above sources. Chi-squared tests were 
performed in order to determine statistical significance between ADRs 
associated with each DOAC, using IBM SPSS 24. A P value of less than 
.05 was considered statistically significant. Because of the exploratory 
nature of this study, the lack of data on potential confounders, and the 
relatively low incidence of some of the ADRs, we used raw data rather 
than disproportionate analysis. The exploratory nature of this study 
also meant that corrections for multiple comparisons were not used.
2.6 | Ethics approval and consent to participate
This study uses publicly available data and no individual level data. It 
therefore does not require ethical approval.
3  | RESULTS
3.1 | Chemistry and pharmacology data
3.1.1 | Chemical properties and pharmacology
The chemical properties and pharmacology of the DOACs are sum-
marized in Table 1. Although all four drugs are termed DOACs, 
Dabigatran has a unique mode of action targeting Thrombin (IC50: 
1.2 nmol/L); Apixaban, Rivaroxaban, and Edoxaban all target Factor 
Xa (IC50 0.08, 0.4 and 0.56 nmol/L respectively), in the clotting cas-
cade. All DOACs show selectivity for their molecular target (Factor 
Xa or thrombin) with modest off-target effects for thrombin/Factor 
Xa and vice versa. Dabigatran is the only DOAC formulated as a 
prodrug form (Dabigatran etexilate).
3.1.2 | Molecular Obesity and risk of off-
target effects
Properties of the DOACs that relate to on-target efficiency (logP, 
IC50, and LLE) are shown in Table 1. Dabigatran has the highest 
logP (5.26) as its prodrug etexilate form and as the active drug 
(2.05). Dabigratran has the lowest LLE as both the active drug 
(6.9)	and	prodrug	 (3.7)	with	the	other	three	DOACs	having	very	
similar LLE values (8.0-8.4). From this holistic measure it can be 
inferred that Dabigatran should have the least clean off-target 
profile.
3.1.3 | Blood-brain barrier penetrant properties
The seven properties of the DOACs relevant to the risk of BBB 
penetration are shown in Table 1. Taken in turn, Rivaroxaban meets 
the	 MW	 requirement	 (435.9	 Da)	 and	 Apixaban	 and	 Dabigatran	
are	 on	 the	 borderline	 (459	 and	 471	 Da,	 respectively).	 Apixaban	
and Rivaroxaban met the requirement for less than six HBAs and 
less than two HBDs. All DOACs are neutral or basic in the given 
form, with only the active form of Dabigatran being an acid. Only 
Rivaroxaban	 meets	 the	 tPSA	 requirement	 (88	 Å).	 Apixaban	 and	
Rivaroxaban meet the logD7.5	 requirements	 at	 1.89	 and	 2.39	 re-
spectively. All DOACs are P-gp substrates. Based on these results 
we would estimate that the greatest risk for BBB penetration would 
be with Rivaroxaban (5 out of 7) followed by Apixaban (4 out of 7). 
Edoxaban (2 out of 7) and Dabigatran (1 out of 7) would have the 
lowest potential risk for BBB penetration.
3.1.4 | Pharmacokinetic information and 
relationship to potential ADRs
The pharmacokinetic profile of the DOACs are shown in Table 1. 
Dabigatran (80%) has the highest renal clearance followed by 
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Rivaroxaban (67%-33%). Importantly, Dabigatran is the only acidic 
DOAC (pKa = 4.25), Dabigatran etexilate is also formulated as a tar-
taric acid salt increasing the localized acidic nature of this DOAC 
which may have implication in resulting GI ADRs compared to 
Apixaban, Edoxaban, or Rivaroxaban.
3.1.5 | Key off-target biological receptors identified 
in the study and links to disease stages
As expected, close members of the clotting cascade inhibition data 
were widely reported (Table 1).
TA B L E  1   Physicochemical, blood-brain barrier, pharmacokinetic and pharmacological properties of the four evaluated drugs
Variable Apixaban Dabigatrana  Edoxaban Rivaroxaban
Molecular obesity and on-target efficiency metrics
log P 2.02 2.05 0.89 1.35
pIC50 (main target) 10.1 8.9 9.3 9.4
LLE 8.1 6.9 8.4 8.0
Blood-brain barrier penetrant properties
MW (Da) 459.5 471.5 548.1 435.9
pKa Neutral 4.25 7.37 neutral
tPSA,	(Å) 108.54 147.47 135.57 88.18
HB acceptors 5 7 8 6
HB donors 1 4 3 1
clog D7.5 1.89 −1.21 0.28 2.39
P-glycoprotein substrate Yes Yes Yes Yes
No. of BBB requirements met 4 1 2 5
Pharmacokinetics
Bioavailability 50% 6.5% 62% 80%
Half-life (hours) 12 8.8 9-11 6-8
Liver CYP450 metabolism Yes Yes Yes Yes
CYP3A4 substrate Yes (~25%) No No Yes (33%)
Renal excretion 25% 80% 35% 67%
Volume of distribution 21 L 60-70 L 107 L 50 L
PPB 87% 35% 55% 95%
Dosing BID OD-BID OD OD-BID
On- and off-target activities
Factor Xa (nmol/L) 0.08 3760 0.561 0.4
Thrombin (nmol/L) 3100 1.2 6000 1000
Factor VIIa (nmol/L) >15 000 — 41 700 >20 000
Factor IXa (nmol/L) >15 000 — — —
Factor XIa (nmol/L) — — — >20 000
Plasmin (nmol/L) >25 000 1695 — >20 000
Plasma Kallikrein (nmol/L) 3700 — — —
APC (nmol/L) >30 000 — — >20 000
tPA (nmol/L) <40 000 45 360 — —
Trypsin (nmol/L) 4200 50.3 — >20 000
Chymotrypsin (nmol/L) 3500 — — —
NQ02 (nmol/L) — 10 000 — —
Matriptase (nmol/L) — — — 3350
Hepsin (nmol/L) — 835 — —
Abbreviations: APC, allophycocyanin; clogD7.5, calculated logD at pH = 7.5 (where D is the distribution coefficient = concentration of solute in 
octanol divided by the concentration of solute in water); HB, hydrogen bond; LLE, lipophilic ligand efficiency; NQ02, Quinone oxidoreductase; tPA, 
tissue plasminogen activator.
aFigures given for active drug only. 
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Apixaban has a high selectivity for Factor Xa over thrombin 
(>38750-fold) and other Factor X isoforms. Potentially clinically 
significant off-targets at a much lower efficacy than the on-target 
(Factor Xa) are plasma Kallikrein (3700 nmol/L), trypsin (4200 nmo-
l/L), and chymotrypsin (3500 nmol/L), all protein degradation 
enzymes in the GIT. The reported tPA data for Apixaban is not a 
specific value: <40 μmol/L. Inhibition of tPA has been linked to pul-
monary embolism.39,40
Dabigatran has good selectivity for thrombin over Factor Xa 
(>3133 fold) but a significant number of potentially biologically rele-
vant off-targets: plasmin (1700 nmol/L), tPA (45 μmol/L), chymotryp-
sin (10 000 nmol/L), NQ02 (10 000 nmol/L), hepsin (835 nmol/L), 
and most potently, trypsin (50 nmol/L) which is 42-fold from the 
desired on-target.
Edoxaban has a good selectivity profile for Factor Xa (0.5 nmo-
l/L) over thrombin (>10 600-fold) and Factor X isoforms (>74 330-
fold). At the time of writing, no nonclotting cascade off-target 
biological data have been disclosed in the literature. Edoxaban 
therefore, has the cleanest off-target profile from the available 
dataset.
Rivaroxaban has a good selectivity profile for Factor Xa over 
thrombin (2500-fold) and the only potentially significant off-target 
affinity being matriptrase (3400 nmol/L). Matriptrase being similar 
in function to trypsin in the GI tract.41
Based on the on-/off-target profiles it would be expected 
that Dabigatran, followed by Apixaban, Rivaroxaban, and finally 
Edoxaban have the greatest number of ADRs overall. The off-target 
potency data for Dabigatran, Apixaban, and Rivaroxaban all point to-
ward an increased risk of GI ADRs. Taken together with Dabigatran's 
acidic formulation, it would be expected that Dabigatran would 
have the highest propensity of all the DOACs for a GI complication. 
Apixaban could potentially be associated with a higher risk of pul-
monary embolism.
3.2 | Overall summary of predictions based on 
chemistry and pharmacology data
1. Based on the molecular obesity and on-/off-target profiles it 
would be expected that, Dabigatran, would have the greatest 
number of ADRs overall.
2. Based on renal clearance it would be expected that, in decreasing 
order, Dabigatran, Rivaroxaban, Edoxaban, and Apixaban would 
have the greatest number of renal ADRs.
3. Based on off-target inhibition of gut proteases and formulations it 
would be expected that Dabigatran and Apixaban would have the 
greater number of GI ADRs.
4. Based on the BBB penetrant molecular properties it would be ex-
pected that Rivaroxaban and Apixaban would be associated with 
the greater number of CNS ADRs.
5. Based on off-target tPA inhibition, it would be expected that 
Dabigatran and Apixaban would be associated with a greater 
number of PE ADRs.
3.3 | Prescription and adverse drug reactions data
Data obtained from the Yellow Card reporting scheme and NHS 
prescribing data were analyzed to confirm or refute the predictions 
formulated above based on the chemical and pharmacological prop-
erties of the individual DOACs.
The number of prescriptions for each DOAC in the United 
Kingdom (up to 2017 for lag detection of ADRs) and number of re-
ported ADRs (2008-2018) and fatalities within the United Kingdom 
are shown in Table 2 together with the P-value for comparison 
across all the DOACs. For the purpose of this research, it was es-
timated that an average of 1 year from when the ADR occurred 
in a patient and when it appears on the Yellow Card Scheme drug 
analysis profiles was an appropriate lag-time which is also the finest 
level of granularity possible with the data available. The individual 
P-values for differences between the individual DOACs are shown 
in	Table	S2.	A	total	of	30	566	936	DOAC	prescriptions	and	22	725	
ADR reports were analyzed. Rivaroxaban had the most prescrip-
tions issued in the timeframe of this study, followed by Apixaban, 
Dabigatran, and Edoxaban.
3.3.1 | Overall adverse drug reactions and fatalities
Overall, Dabigatran (0.20%) had the highest percentage of ADRs 
relative to the total number of prescriptions followed by Edoxaban 
(0.13%), Rivaroxaban (0.11%), and Apixaban (0.07%). Standardizing 
for a typical daily dose equivalent (DDE) the following trend 
emerged in the percentage of ADRs reported; Edoxaban (0.13%), 
Rivaroxaban (0.06%-0.11%), Dabigatran (0.10%), and Apixaban 
(0.02%-0.04%). The high percentage ADRs for Edoxaban are likely 
due to its black triangle status. A similar trend was observed for 
fatalities	with	Dabigatran	 having	 the	most	 (7.92%)	 and	Apixaban	
(2.36%) the least proportionate to the number of prescriptions 
(Edoxaban (3.42%), Rivaroxaban (3.38%)). On standardizing for 
DDE fatalities the following trend is observed; Dabigatran (3.46%), 
Edoxaban	 (3.42%),	 Rivaroxaban	 (1.69%-3.38%),	 and	 Apixaban	
(0.59%-1.18%).	 Due	 to	 complications	 resulting	 from	 how	 the	
DOACs are prescribed depending on the indication ranging from 
1, 2, or 4 tablets per day, the following data are normalized to the 
number of prescription items.
3.3.2 | Renal adverse drug reactions and fatalities
The highest risk of renal ADRs was associated with Dabigatran, 
Rivaroxaban, Edoxaban, and Apixaban in descending order. The 
major reported renal ADR was acute kidney injury (AKI) accounting 
for 23.7% of all renal ADRs. The highest risk of AKI occurred with 
Dabigatran (1.60 per 100 000 prescriptions), Rivaroxaban (0.45), 
and Apixaban (0.34) with no AKI reports associated with the use of 
Edoxaban. There were five renal fatalities attributed to DOACs dur-
ing the timeline of this retrospective study.
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3.3.3 | Gastrointestinal adverse drug 
reactions and fatalities
For all DOACs, the gastrointestinal tract (GIT) was the organ with the 
highest reported ADRs. Dabigatran had a GI ADR rate of 55.27 per 
100 000 prescriptions, significantly higher than Edoxaban (27.42), 
Rivaroxaban (21.50), or Apixaban (12.41).
Within GI hemorrhage, Dabigatran recorded the highest num-
ber of ADRs at 20.74 per 100 000 prescriptions, followed by 
Rivaroxaban	 (9.62),	 Edoxaban	 (9.14),	 and	 Apixaban	 (5.44).	 These	
ADR levels bear out within the GI hemorrhage fatality figures at 1.85 
per 100 000 prescriptions for Dabigatran, followed by Rivaroxaban 
(0.47), Apixaban (0.35), and Edoxaban at 0.34 (on the basis of a single 
fatality).
3.3.4 | Central nervous system adverse drug 
reactions and fatalities
For all DOACS, the CNS was the organ system with the second 
highest reported ADRs. Dabigatran had the highest proportion of 
reported CNS ADRs with 23.41 per 100 000 prescriptions, fol-
lowed	 by	 Edoxaban	 (21.66),	 Rivaroxaban	 (15.91),	 and	 Apixaban	
(11.53). Dabigatran, Rivaroxaban, and Apixaban had the high-
est number of fatal outcomes within the central nervous system 
category	 at	 1.80,	 1.09,	 respectively	 per	 100	 000	 prescriptions	
(Edoxaban, 1.02).
Edoxaban had the highest number of stroke ADRs per 100 000 
prescriptions at 3.38, followed by Dabigatran (3.11), Apixaban 
(1.15), and Rivaroxaban (0.65). A different trend emerged within the 
fatal stroke category with Dabigatran being the highest at 0.24 per 
100 000 prescriptions, followed by Apixaban (0.18) and Rivaroxaban 
(0.16). No stroke fatalities were attributed to Edoxaban.
Rivaroxaban had the highest proportion of hemorrhagic strokes 
at	0.39	per	100	000	prescriptions,	followed	by	Apixaban	(0.30)	and	
Dabigatran (0.24). None were reported for Edoxaban.
3.3.5 | Respiratory system adverse drug 
reactions and fatalities
Dabigatran had the highest number of reported ADRs associated 
with the pulmonary system at 12.58 per 100 000 prescriptions fol-
lowed by Rivaroxaban (7.78), Edoxaban (4.74), and Apixaban (4.46).
Overall there were 32 respiratory system deaths attributed to 
DOACs	with	Dabigatran	having	the	highest	proportion	at	0.49	per	
Apixaban Dabigatran Rivaroxaban Edoxaban P-value
Total prescriptions 8 471 045 2	059	119 10 741 318 295	454
Total ADRs 5874	(69) 4050	(197) 11 860 (110) 385 (130) <0.001
Fatalities 200 (2.36) 163	(7.92) 368 (3.42) 10 (3.38) <0.001
Renal system
Total ADRs 169	(2.00) 139	(6.75) 389	(3.62) 8 (2.71) <0.001
Fatalities 3 (0.04) 0 (0) 2 (0.02) 0 (0) 0.756
AKI 29	(0.34) 33 (1.60) 48 (0.45) 0 (0) <0.001
Gastrointestinal system
Total ADRs 1051 (12.41) 1138 (55.27) 2309	(21.50) 81 (27.42) <0.001
Fatalities 29	(0.34) 38 (1.85) 52 (0.48) 1 (0.34) <0.001
GI Hemorrhage 461 (5.44) 427 (20.74) 1033	(9.62) 27	(9.14) <0.001
Fatal GI 
Hemorrhage
30 (0.35) 38 (1.85) 51 (0.47) 1 (0.34) <0.001
Central nervous system
Total ADRs 977	(11.53) 482 (23.41) 1709	(15.91) 64 (21.66) <0.001
Fatalities 92	(1.09) 37 (1.80) 177 (1.65) 3 (1.02) 0.005
Stroke 97	(1.15) 64 (3.11) 102	(0.95) 10 (3.38) <0.001
Fatal stroke 15 (0.18) 5 (0.24) 17 (0.16) 0 (0) 0.742
Hemorrhagic 
stroke
25 (0.30) 5 (0.24) 42	(0.39) 0 (0) 0.403
Respiratory system
Total ADRS 378 (4.46) 259	(12.58) 836 (7.78) 14 (4.74) <0.001
Fatalities 5 (0.06) 10	(0.49) 17 (0.16) 0 (0) <0.001
Pulmonary 
embolism
57 (0.67) 75 (3.64) 131 (1.22) 2 (0.68) <0.001
TA B L E  2   Summary of the reported 
adverse drug reactions associated with 
all four currently available DOACs in the 
UK. Numbers in brackets are per 100 000 
prescriptions. P-values obtained by Chi-
square analysis detailed in the supporting 
information
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100 000 prescriptions followed by Rivaroxaban (0.16) and Apixaban 
(0.06) with no respiratory deaths attributed to Edoxaban.
For pulmonary embolism, Dabigatran had the highest number 
per 100 000 prescriptions at 3.64, followed by Rivaroxaban (1.22), 
and Edoxaban (0.68), and Apixaban (0.67).
4  | DISCUSSION
Based on the chemistry and pharmacology data we obtained from all 
four DOACs, we made several predictions on the ADRs that would 
have been reported for each individual DOAC. In general terms, our 
predictions held true supporting our initial premise that the chemi-
cal and pharmacological properties of each DOAC could be used to 
guide targeted postmarketing drug surveillance.
4.1 | Overall adverse drug reactions and fatalities
Based on the chemical properties relating to on-target efficiency 
(logP, IC50, and LLE) we predicted that Dabigatran would have 
the least clean off-target profile. This was indeed the case with 
Dabigatran having several off-target activities in the micromolar 
range. Our prediction that Dabigatran would have the most over-
all	ADRs	also	held	true	with	a	rate	of	197	ADRs	per	100	000	pre-
scriptions compared to the next highest, Rivaroxaban, with a rate of 
110 per 100 000 prescriptions. This finding was also supported by 
Dabigatran	having	the	highest	rate	of	fatalities	reported	at	7.92	per	
100 000 prescriptions. This is more than double the next highest, 
Rivaroxaban at 3.42 per 100 000 prescriptions crudely suggesting 
that the severity, and not just the frequency, of ADRs is highest with 
Dabigatran out of the four DOACs. Dabigatran is currently the least 
prescribed of the three established DOACs, Edoxaban has been li-
censed only since 2015 and is under Black Triangle reporting status 
with the MHRA. This lower prescribing rate has been attributed to 
the well-recognized higher risk of GI hemorrhage associated with 
Dabigatran.42
4.2 | Renal adverse drug reactions and fatalities
There is a link between renal clearance pathways and percentage 
of renal ADRs relative to total prescriptions.43 The higher the renal 
clearance, the higher the percentage of renal reactions. The rea-
soning being if a DOAC has higher renal clearance then the kidneys 
are processing a higher amount of drug and are at a greater risk 
of experiencing a renal ADR especially with declining renal func-
tion.44 As predicted, Dabigatran having the highest proportion of 
renal clearance at 80% had the highest rate of renal ADRs out of 
all DOACs.
The major reported renal ADR extracted from the Yellow Card 
Scheme for Dabigatran is AKI and Dabigatran had the highest in-
cidence with 1.60 events per 100 000 prescriptions. The cause or 
nature of the AKI cannot be discerned from the Yellow Card data. 
However, it has become increasingly apparent that the syndrome 
of warfarin-induced nephropathy,that is intraglomerular hem-
orrhage leading to AKI, also happens with the use of DOACs.45 
Therefore, DOAC nephropathy is potentially the cause of AKI re-
ported ADRs.
4.3 | Gastrointestinal adverse drug 
reactions and fatalities
GI ADRs remain the most commonly reported and well-documented 
reaction for the DOACs, in particular, GI hemorrhage.46-48 DOACs 
have an increased risk of GI hemorrhage compared to the VKAs with 
a relative risk of 1.25.49 However, no research has defined the un-
derlying cause, other than their mode of action. Suggestions as to 
why the DOACs cause GI hemorrhage, include: incomplete absorp-
tion; and tartaric acid in the Dabigatran formulation causing a di-
rect effect or inhibition of mucosal healing.42 Dabigatran is the only 
DOAC to contain an acid and would be the only DOAC to lead to 
GI hemorrhage through a direct caustic effect. Dabigatran is associ-
ated with the highest percentage of GI ADRs in relation to prescrip-
tions (Table 2). Edoxaban appears to also have a high proportion of 
GI ADRs relative to prescriptions (Table 2) and this data could be 
misleading due to the short time the drug has been licensed for and 
therefore the small number of ADRs and prescriptions potentially 
artificially inflating the number of reported ADRs in relation to other 
DOACs.
Our data confirm that Dabigatran is associated with the high-
est risk of GI hemorrhage. The data also support the fact that 
Rivaroxaban is the DOAC associated with the second largest risk of 
GI hemorrhage (Table 2). As Dabigatran is the DOAC with consis-
tently high GI ADRs and incidences of GI hemorrhage throughout 
preclinical, clinical trial, and postmarketing data, it is unsurprising 
that it is also associated with the highest percentage of total GI fa-
talities. It is over 2-fold that of other DOACs (Table 2) and GI hem-
orrhage accounts for the highest number of deaths within this organ 
class. For all DOACs, GI hemorrhage contributes to the highest 
number of fatal reports within the GI organ class. This suggests that 
DOACs with the highest risk of GI hemorrhage are also those with 
the highest risk of GI death.
Dabigatran targets the protease, trypsin (potently), 
Rivaroxaban (matriptase, modestly) and Apixaban target chy-
motrypsin (but only at the upper limit of clinical relevance), but 
importantly, Edoxaban targets neither. Trypsin, chymotrypsin, 
and matriptase are digestive enzymes found within the GI tract 
and their secretion leads to mucosal vulnerability that in turn, 
makes the GIT more prone to gastric bleeding.50 Through binding 
interactions with the DOACs, these enzymes become trapped 
within the GIT and lead to increased mucosal vulnerability and 
thus increased rates of GI hemorrhage and fatalities. Apixaban 
binds with weak affinity; this would explain why the GI hemor-
rhage risk is not high. Rivaroxaban should be between Apixaban 
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and Dabigatran in terms of risk. Dabigatran's binding affinity to 
Trypsin is potent (50.3 nmol/L) and along with the tartaric acid 
present in the formulation, renders the GI mucosa even more vul-
nerable to hemorrhage,50 potentially explaining the high number 
of reports related to GI ADRs and in particular GI hemorrhage. 
Dabigatran also has an acidic pKa, further increasing the vulnera-
bility of the GI mucosa. In addition, Apixaban and Dabigatran are 
associated with poor bioavailability (Table 1), and as both drugs 
are absorbed via the GIT, the remainder of the unabsorbed drug 
remains within the GIT. The drug will have local anticoagulation 
effects within the GIT, leading to GI ADRs such as GI discomfort, 
dysphagia, and also GI hemorrhage. As Dabigatran has poor bio-
availability at 6.5%, the local effects would be more pronounced 
than for Apixaban which has a bioavailability of 50%, further ex-
plaining the higher percentage of GI ADRs and GI hemorrhage 
for Dabigatran.
4.4 | Central nervous system adverse drug 
reactions and fatalities
Nervous system ADRs are the second most frequent reactions 
reported across all DOACs within the United Kingdom. Based on 
the BBB penetrant properties of the four DOACs we predicted 
that Rivaroxaban would be associated with the highest num-
ber of CNS ADRs. However, this was not the case for total CNS 
ADRs, reported CNS fatalities, all stroke, fatal stroke and hem-
orrhagic stroke. Indeed, the highest rates were largely seen with 
Dabigatran which only had one BBB penetrant property compared 
with Rivaroxaban that had five. It is not clear why this should be, 
but might be related purely to an enhanced risk of CNS bleeding 
with Dabigatran. However, our results call into question a simple 
interpretation of the number BBB penetrant properties to predict 
CNS ADRs.
4.5 | Pulmonary embolism
We predicted Dabigatran and Apixaban would be associated 
with the highest rates of reported pulmonary embolic events. 
Although this held true for Dabigatran it was not so for Apixaban. 
Dabigatran and Apixaban, both target tPA, a serine protease that 
has fibrinolytic activity and can break down blood clots within the 
body.40 It has also been used to treat PE.39 The reported tPA data 
for Apixaban is not specifically documented, however, Dabigatran, 
has a known affinity of 45 μmol/L. Dabigatran inhibits tPA, inhibit-
ing fibrinolytic activity, resulting in reduced breakdown of blood 
clots. This could potentially be a reason as to why Dabigatran pro-
vides the highest relative amount of PE ADRs compared to the 
other DOACs.
It should also be noted that all DOACs investigated can be pre-
scribed for PE and stroke, and therefore, these ADR classifications 
may result from the clinical diagnosis for prescribing the DOAC.
4.6 | Limitations
Data on the DOACs were obtained using Interactive Drug Analysis 
Profiles from the MHRA. Drug Analysis Profiles gave a complete 
listing of all the spontaneous suspected ADRs reported through the 
Yellow Card Scheme by healthcare professionals, patients, and the 
pharmaceutical industry in the United Kingdom irrespective of other 
drugs taken or comorbidities. Covariate data analysis could there-
fore not be conducted. As such, the data within represents postmar-
keting phase IV data with real-world patients. They do not however, 
present a complete overview of the risks associated with specific 
medicines. Conclusions on the safety and risks of medicines cannot 
therefore be made on the information contained in Drug Analysis 
Profiles alone,51 only signal (hypothesis) generation.
In addition, it cannot be concluded that there is a definite 
causal link between the drug and the adverse patient event that 
has been reported until further investigations have occurred. It 
may also be difficult to determine the difference between a reac-
tion that occurred naturally as a result of the disease being treated 
(eg, PE or stroke) and an ADR. Therefore, only enhanced signals 
compared to the baseline or where disparate levels of ADRs be-
tween the well-established DOACs were interpreted in this study 
(Charts S1 and S2).
5  | CONCLUSIONS
The emergence of DOACs in the late 2000s has altered the treat-
ment for thromboembolic diseases, including AF and stroke. The 
safety of DOACs has remained an ongoing topic of research due 
to risks of certain increased bleeds compared to warfarin. We 
have established a correlation between physicochemical and 
pharmacological properties, which reflect drug-target interaction 
in vivo. This work firstly corroborates the existing literature on 
GI hemorrhage in DOACs but new findings regarding stroke and 
AKI can be tentatively linked to the mode of action and selectiv-
ity profile. Indeed, three of the five predictions made based on 
the pharmacological and chemical properties of the DOACs have 
been supported by interpretation of the UK Yellow Card database 
and were statistically validated. However, we recommend close 
monitoring for pulmonary embolism going forward, as current 
data are limited.
In summary, we propose the use of pharmacological and chemi-
cal data as a forward-looking predictor of drug liabilities in phase IV 
monitoring, in conjunction with real-time adverse event reporting, 
to identify early risks with novel drugs. Furthermore, the predictions 
made using this data, backed up by the reported ADR data, could 
potentially be used by clinicians to select the appropriate DOAC for 
an individual patient.
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